Michael A Gorin1, Hiten D Patel2, Steven P Rowe3, Noah M Hahn4, Hans J Hammers5, Alice Pons6, Bruce J Trock2, Phillip M Pierorazio4, Thomas R Nirschl6, Daniela C Salles7, Julie E Stein7, Tamara L Lotan7, Janis M Taube8, Charles G Drake9, Mohamad E Allaf10. 1. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 6. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Bloomberg~Kimmel Institute for Cancer Immunotherapy and The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 8. Bloomberg~Kimmel Institute for Cancer Immunotherapy and The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 9. Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA. 10. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: mallaf@jhmi.edu.
Abstract
Neoadjuvant immune checkpoint blockade represents a novel approach for potentially decreasing the risk of recurrence in patients with nonmetastatic renal cell carcinoma (RCC). In this early phase clincal tiral, we evaluated the safety and tolerability of neoadjuvant treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab in patients with nonmetastatic high-risk RCC. Nonprimary endpoints included objective radiographic tumor response rate, immune-related pathologic response rate, quality of life alterations, and metastasis-free and overall survival. In total, 17 patients were enrolled in this study and underwent surgery without a delay after receiving three every-2-wk doses of neoadjuvant nivolumab. Adverse events (AEs) of any grade occurred in 14 (82.4%) patients, with two (11.8%) experiencing grade 3 events. Ten (58.8%) patients experienced an AE of any grade potentially attributable to nivolumab (all grade 1-2), and no grade 4-5 AEs occurred regardless of treatment attribution. The most common AEs were grade 1 fatigue (41.2%), grade 1 pruritis (29.4%), and grade 1 rash (29.4%). All evaluable patients had stable disease as per established radiographic criteria, with one (6.7%) demonstrating features of an immune-related pathologic response. Quality of life remained stable during treatment, with improvements relative to baseline noted at ≥6 mo postoperatively. Metastasis-free survival and overall survival were 85.1% and 100% at 2 yr, respectively. PATIENT SUMMARY: In this study, we evaluated the safety and tolerability of preoperative administration of three doses of the immune checkpoint inhibitor nivolumab in patients with clinically localized high-risk renal cell carcinoma. We demonstrated the safety of this approach and found that, although most patients will not experience a radiographic response to treatment, a subset may have features of an immune-related pathologic response.
Neoadjuvant immune checkpoint blockade represents a novel approach for potentially decreasing the risk of recurrence in patients with nonmetastatic renal cell carcinoma (RCC). In this early phase clincal tiral, we evaluated the safety and tolerability of neoadjuvant treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab in patients with nonmetastatic high-risk RCC. Nonprimary endpoints included objective radiographic tumor response rate, immune-related pathologic response rate, quality of life alterations, and metastasis-free and overall survival. In total, 17 patients were enrolled in this study and underwent surgery without a delay after receiving three every-2-wk doses of neoadjuvant nivolumab. Adverse events (AEs) of any grade occurred in 14 (82.4%) patients, with two (11.8%) experiencing grade 3 events. Ten (58.8%) patients experienced an AE of any grade potentially attributable to nivolumab (all grade 1-2), and no grade 4-5 AEs occurred regardless of treatment attribution. The most common AEs were grade 1 fatigue (41.2%), grade 1 pruritis (29.4%), and grade 1 rash (29.4%). All evaluable patients had stable disease as per established radiographic criteria, with one (6.7%) demonstrating features of an immune-related pathologic response. Quality of life remained stable during treatment, with improvements relative to baseline noted at ≥6 mo postoperatively. Metastasis-free survival and overall survival were 85.1% and 100% at 2 yr, respectively. PATIENT SUMMARY: In this study, we evaluated the safety and tolerability of preoperative administration of three doses of the immune checkpoint inhibitor nivolumab in patients with clinically localized high-risk renal cell carcinoma. We demonstrated the safety of this approach and found that, although most patients will not experience a radiographic response to treatment, a subset may have features of an immune-related pathologic response.
Authors: Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245
Authors: Jose A Karam; Catherine E Devine; Diana L Urbauer; Marisa Lozano; Tapati Maity; Kamran Ahrar; Pheroze Tamboli; Nizar M Tannir; Christopher G Wood Journal: Eur Urol Date: 2014-02-07 Impact factor: 20.096
Authors: Jose A Karam; Catherine E Devine; Bryan M Fellman; Diana L Urbauer; E Jason Abel; Mohamad E Allaf; Axel Bex; Brian R Lane; R Houston Thompson; Christopher G Wood Journal: BJU Int Date: 2015-06-29 Impact factor: 5.588
Authors: Hiten D Patel; Maneka Puligandla; Brian M Shuch; Bradley C Leibovich; Anil Kapoor; Viraj A Master; Charles G Drake; Daniel Yc Heng; Primo N Lara; Toni K Choueiri; Deborah Maskens; Eric A Singer; Scott E Eggener; Robert S Svatek; Walter M Stadler; Suzanne Cole; Sabina Signoretti; Rajan T Gupta; Marc Dror Michaelson; David F McDermott; David Cella; Lynne I Wagner; Naomi B Haas; Michael A Carducci; Lauren C Harshman; Mohamad E Allaf Journal: Future Oncol Date: 2019-04-10 Impact factor: 3.404
Authors: Craig Labbate; Ken Hatogai; Ryan Werntz; Walter M Stadler; Gary D Steinberg; Scott Eggener; Randy F Sweis Journal: J Immunother Cancer Date: 2019-03-11 Impact factor: 13.751
Authors: Nirmish Singla; Roy Elias; Rashed A Ghandour; Yuval Freifeld; Isaac A Bowman; Leonid Rapoport; Mikhail Enikeev; Jay Lohrey; Solomon L Woldu; Jeffrey C Gahan; Aditya Bagrodia; James Brugarolas; Hans J Hammers; Vitaly Margulis Journal: Urol Oncol Date: 2019-09-12 Impact factor: 2.954
Authors: Maria I Carlo; Kyrollis Attalla; Yousef Mazaheri; Sounak Gupta; Onur Yildirim; Samuel J Murray; Devyn T Coskey; Ritesh Kotecha; Chung-Han Lee; Darren R Feldman; Paul Russo; Sujata Patil; Robert J Motzer; Jonathan A Coleman; Jeremy C Durack; Ying-Bei Chen; Oguz Akin; A Ari Hakimi; Martin H Voss Journal: Eur Urol Date: 2022-02-17 Impact factor: 24.267
Authors: Grant D Stewart; Sarah J Welsh; Stephan Ursprung; Ferdia A Gallagher; James O Jones; Jacqui Shields; Christopher G Smith; Thomas J Mitchell; Anne Y Warren; Axel Bex; Ekaterini Boleti; Jade Carruthers; Tim Eisen; Kate Fife; Abdel Hamid; Alexander Laird; Steve Leung; Jahangeer Malik; Iosif A Mendichovszky; Faiz Mumtaz; Grenville Oades; Andrew N Priest; Antony C P Riddick; Balaji Venugopal; Michelle Welsh; Kathleen Riddle; Lisa E M Hopcroft; Robert J Jones Journal: Br J Cancer Date: 2022-06-23 Impact factor: 9.075